Patients using icodec tend to have a higher incidence of hypoglycemic events compared to glargine or degludec, especially on days 2–4 of the weekly dosing cycle.
Researchers introduce the “4S Pathway” to help manage diabetes regimens in older individuals experiencing difficulties with their current glycemic management approach.
